Vascular endothelial growth factor in human lung transplantation.
OBJECTIVE
To determine levels of the vascular endothelial growth factor (VEGF) isoform consisting of 165 amino acids (VEGF(165)) in BAL fluid (BALF) from lung transplant recipients (LTXs).


METHODS
Bronchoscopy with BAL was performed on LTXs and normal volunteers (NVs).


METHODS
University hospital.


METHODS
LTXs (n = 57) and NVs (n = 15). MEASUREMENTS AND RESULT: VEGF(165) concentrations in BALF were higher (mean +/- SEM, 240 +/- 32 pg/mL) for NVs (n = 15) vs 133 +/- 14 pg/mL for LTXs (n = 37) who were stable without evidence of significant rejection or infection at 6 months after transplantation (p < 0.0001). BALF VEGF concentrations sampled at 24 to 48 h, 2 weeks, 4 weeks, and 6 months after transplantation for 11 LTXs who lacked rejection or infection at any time point were 71 +/- 8 pg/mL, 80 +/- 20 pg/mL, 82 +/- 13 pg/mL, and 167 +/- 31 pg/mL, respectively. VEGF concentrations in BALF for LTXs with cytomegalovirus (CMV) pneumonia were 55 +/- 12 pg/mL (n = 10), 117 +/- 33 pg/mL for grade A3 acute rejection (n = 9), and 82 +/- 17 pg/mL (n = 14) for active bronchiolitis obliterans syndrome (BOS). Concentrations of VEGF in BALF at 6 months for the 32 stable recipients with bilateral lung transplantation were significantly higher for those with higher values for FEV(1), and BALF VEGF concentrations were significantly lower in BALF at 6 months for those recipients who subsequently went on to develop BOS (86 +/- 19 pg/mL) vs those who did not (158 +/- 18 pg/mL; p = 0.03). Serum concentrations of VEGF did not correlate with VEGF concentrations in BALF, but serum VEGF was 291 +/- 62 pg/mL at 10 to 14 days after transplantation vs 130 +/- 20 pg/mL at 4 weeks for nine LTXs with paired samples (p < 0.02). Serum VEGF concentrations for NVs (n = 15) were 102 +/- 15 pg/mL vs 94 +/- 17 for stable LTXs (n = 12) at 24 weeks after transplantation and 123 +/- 33 pg/mL for LTXs with active BOS (n = 10).


CONCLUSIONS
BALF VEGF concentrations are particularly depressed at early time points following lung transplantation, gradually improve in the absence of significant rejection or infection, and are lower with active rejection or CMV pneumonia.
Meyer
K C
KC
Department of Medicine, University of Wisconsin Medical School, Madison, WI, USA. kcm@medicine.wisc.edu
Cardoni
A L
AL
Xiang
Z
Z
Cornwell
R D
RD
Love
R B
RB
D001992:Bronchoalveolar Lavage Fluid; D001999:Bronchoscopy; D003586:Cytomegalovirus Infections / Q000175:diagnosis* / Q000503:physiopathology; D016228:Endothelial Growth Factors / Q000378:metabolism*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000175:diagnosis* / Q000503:physiopathology; D006801:Humans; D016040:Lung Transplantation / Q000502:physiology*; D008222:Lymphokines / Q000378:metabolism*; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000503:physiopathology; D011024:Pneumonia, Viral / Q000175:diagnosis* / Q000503:physiopathology; D012016:Reference Values; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors